Ranbaxy shares slump after Daiichi Sankyo says misled
"Daiichi Sankyo believes that certain former shareholders of Ranbaxy Laboratories concealed and misrepresented critical information concerning the US DOJ and FDA investigations," the Japanese company said in a statement on its website late on Wednesday, referring to the US Department of Justice and the Food and Drug Administration.
Ranbaxy Laboratories Ltd slumped as much as 6.97 percent on Thursday after majority shareholder Daiichi Sankyo Co said it believes former shareholders of the Indian company hid information regarding US regulatory probes.
Also read: Ranbaxy falls 7%, Daiichi may sue ex-promoters
"Daiichi Sankyo believes that certain former shareholders of Ranbaxy concealed and misrepresented critical information concerning the US DOJ and FDA investigations," the Japanese company said in a statement on its website late on Wednesday, referring to the US Department of Justice and the Food and Drug Administration.
Daiichi Sankyo did not name the shareholders. Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
